SynCore Biotechnology Co (ROCO:4192) ROCE % : 63.45% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is SynCore Biotechnology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SynCore Biotechnology Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 63.45%.

SynCore Biotechnology Co ROCE % Historical Data

The historical data trend for SynCore Biotechnology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynCore Biotechnology Co ROCE % Chart

SynCore Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-59.27

-66.12

-90.52

-53.80

-12.32

SynCore Biotechnology Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-111.48	-39.85	-49.38	-64.32	63.45

SynCore Biotechnology Co ROCE % Calculation

SynCore Biotechnology Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-37.388	/	( ( (436.648 - 186.644)	+	(378.362 - 21.226) )	/ 2 )
	=	-37.388	/	( (250.004	+	357.136)	/ 2 )
	=	-37.388	/	303.57
	=	-12.32 %

SynCore Biotechnology Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	166.516	/	( ( (279.714 - 111.978)	+	(378.362 - 21.226) )	/ 2 )
	=	166.516	/	( ( 167.736	+	357.136 )	/ 2 )
	=	166.516	/	262.436
	=	63.45 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

SynCore Biotechnology Co (ROCO:4192) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SynCore Biotechnology Co ROCE % Related Terms

Thank you for viewing the detailed overview of SynCore Biotechnology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SynCore Biotechnology Co (ROCO:4192) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynCore Biotechnology Co Ltd (ROCO:4192) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269

Website

https://www.syncorebio.com

SynCore Biotechnology Co Ltd is a biopharmaceutical company. Its pipeline products concentrate on the ophthalmology, oncology, and dermatology fields. The pipeline products of the company include SB01 and 02, SB03, SB04, and SB05. It is engaged in drug development and sale, food advisory, medicine inspection, biotechnology service and intellectual property. It operates in a single industry, the new drug development.

SynCore Biotechnology Co (ROCO:4192) Headlines

No Headlines